

Applicants: Vered Rosenberger, et al.
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 4

Amendments to the Claims:

Please cancel claims 2-58, 60-77, and 79-88 without disclaimer or prejudice to applicants' right to pursue the subject matters of these claims in the future.

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A pharmaceutical composition comprising a nanoparticle and any one of a peptide, a polysaccharide, or a glycoprotein, attached electrostatically thereto, and a pharmaceutically acceptable carrier.

2-58. (Canceled)

59. (Original) A method of inhibiting enzymatic degradation of a peptide, a polysaccharide, or a glycoprotein upon oral ingestion of the peptide, the polysaccharide, or the glycoprotein by an animal, comprising electrostatically attaching the peptide, the polysaccharide, or the glycoprotein to a nanoparticle prior to the oral ingestion, so as to thereby inhibit enzymatic degradation of the peptide, the polysaccharide, or the glycoprotein upon oral ingestion..

60-77. (Canceled)

78. (Original) A method of treating a subject afflicted with relapsing remitting multiple sclerosis which comprises oral administration of a nanoparticulate formulation of glatiramer acetate, wherein the amount of glatiramer

Applicants: Vered Rosenberger, et al.

U.S. Serial No.: Not Yet Known

Filed: Herewith

Page 5

acetate in the nanoparticulate formulation is effective to alleviate a symptom of the relapsing-remitting multiple sclerosis in the subject.

79-88. (Cancelled)